See more : Embark Education Group Limited (EVO.NZ) Income Statement Analysis – Financial Results
Complete financial analysis of Prothena Corporation plc (PRTA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Prothena Corporation plc, a leading company in the Biotechnology industry within the Healthcare sector.
- Arctic Paper S.A. (ARP.ST) Income Statement Analysis – Financial Results
- Sitronix Technology Corporation (8016.TW) Income Statement Analysis – Financial Results
- Osaki Electric Co., Ltd. (6644.T) Income Statement Analysis – Financial Results
- Patriot Battery Metals Inc. (PMT.AX) Income Statement Analysis – Financial Results
- Grindrod Limited (GND.JO) Income Statement Analysis – Financial Results
Prothena Corporation plc (PRTA)
About Prothena Corporation plc
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 91.37M | 53.91M | 200.58M | 853.00K | 814.00K | 955.00K | 27.52M | 1.06M | 1.61M | 50.85M | 676.00K | 2.66M | 507.00K | 1.24M |
Cost of Revenue | 220.57M | 6.74M | 82.28M | 74.88M | 50.84M | 101.18M | 134.55M | 119.53M | 58.44M | 38.45M | 26.05M | 34.14M | 0.00 | 0.00 |
Gross Profit | -129.20M | 47.16M | 118.29M | -74.03M | -50.02M | -100.23M | -107.03M | -118.48M | -56.83M | 12.40M | -25.38M | -31.48M | 507.00K | 1.24M |
Gross Profit Ratio | -141.40% | 87.49% | 58.98% | -8,678.90% | -6,145.21% | -10,495.08% | -388.92% | -11,230.24% | -3,536.53% | 24.39% | -3,753.85% | -1,184.39% | 100.00% | 100.00% |
Research & Development | 220.57M | 135.56M | 82.28M | 74.88M | 50.84M | 101.18M | 134.55M | 119.53M | 58.44M | 38.45M | 26.05M | 34.14M | 24.17M | 9.79M |
General & Administrative | 61.84M | 49.90M | 46.32M | 38.70M | 35.74M | 42.48M | 48.23M | 41.06M | 23.11M | 19.05M | 15.05M | 9.93M | 5.58M | 3.62M |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 61.84M | 49.90M | 46.32M | 38.70M | 35.74M | 42.48M | 48.23M | 41.06M | 23.11M | 19.05M | 15.05M | 9.93M | 5.58M | 3.62M |
Other Expenses | 0.00 | 5.95M | -54.00K | 1.31M | 8.40M | 2.74M | -2.35M | 571.00K | 26.00K | 310.00K | -225.00K | 0.00 | 0.00 | 0.00 |
Operating Expenses | 282.41M | 185.46M | 128.60M | 113.59M | 86.57M | 143.67M | 182.77M | 160.59M | 81.54M | 57.50M | 41.10M | 44.07M | 29.75M | 13.41M |
Cost & Expenses | 282.41M | 185.46M | 128.60M | 113.59M | 86.57M | 143.67M | 182.77M | 160.59M | 81.54M | 57.50M | 41.10M | 44.07M | 29.75M | 13.41M |
Interest Income | 31.01M | 6.35M | 42.00K | 1.37M | 8.20M | 6.39M | 3.55M | 0.00 | 196.00K | 79.00K | 71.00K | 5.00K | 0.00 | 0.00 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 8.20M | 3.70M | 3.69M | 0.00 | 0.00 | 0.00 | 154.00K | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 928.00K | 6.74M | 6.80M | 6.98M | 6.82M | 3.22M | 3.07M | 2.43M | 806.00K | 743.00K | 660.00K | 468.00K | 391.00K | 191.00K |
EBITDA | -190.11M | -131.56M | 71.98M | -111.22M | -78.94M | -152.90M | -152.19M | -156.54M | -79.13M | -5.91M | -39.77M | -40.94M | -28.85M | -11.97M |
EBITDA Ratio | -208.06% | -244.05% | 35.88% | -13,216.18% | -10,542.87% | -13,252.88% | -564.17% | -15,121.80% | -4,974.30% | -13.07% | -5,980.33% | -1,557.94% | -5,690.93% | -963.07% |
Operating Income | -191.04M | -131.56M | 71.98M | -112.73M | -85.70M | -158.86M | -155.25M | -159.54M | -79.94M | -6.65M | -40.43M | -41.41M | -29.24M | -12.16M |
Operating Income Ratio | -209.08% | -244.05% | 35.88% | -13,216.18% | -10,527.89% | -16,634.03% | -564.17% | -15,121.80% | -4,974.30% | -13.07% | -5,980.33% | -1,557.94% | -5,768.05% | -978.44% |
Total Other Income/Expenses | 30.56M | 5.95M | -54.00K | 1.31M | 8.40M | 2.74M | -2.35M | 571.00K | 26.00K | 310.00K | -154.00K | 5.00K | 0.00 | 0.00 |
Income Before Tax | -160.48M | -125.61M | 71.92M | -111.43M | -77.30M | -156.12M | -157.60M | -158.96M | -79.91M | -6.34M | -40.58M | -41.41M | -29.24M | -12.16M |
Income Before Tax Ratio | -175.64% | -233.01% | 35.86% | -13,062.95% | -9,496.07% | -16,347.12% | -572.71% | -15,067.68% | -4,972.68% | -12.47% | -6,003.11% | -1,557.75% | -5,768.05% | -978.44% |
Income Tax Expense | -13.45M | -8.66M | 4.95M | -283.00K | 379.00K | -470.00K | -4.37M | 1.14M | 701.00K | 811.00K | 415.00K | 6.00K | 426.00K | 320.00K |
Net Income | -147.03M | -116.95M | 66.98M | -111.14M | -77.68M | -155.65M | -153.24M | -160.11M | -80.61M | -7.15M | -41.00M | -41.41M | -29.67M | -12.48M |
Net Income Ratio | -160.91% | -216.95% | 33.39% | -13,029.78% | -9,542.63% | -16,297.91% | -556.84% | -15,176.11% | -5,016.30% | -14.06% | -6,064.50% | -1,557.98% | -5,852.07% | -1,004.18% |
EPS | -2.76 | -2.47 | 1.51 | -2.78 | -1.95 | -3.93 | -4.07 | -4.66 | -2.66 | -0.29 | -2.20 | -2.84 | -1.68 | -0.71 |
EPS Diluted | -2.76 | -2.47 | 1.38 | -2.78 | -1.95 | -3.93 | -4.07 | -4.66 | -2.66 | -0.29 | -2.20 | -2.84 | -1.68 | -0.71 |
Weighted Avg Shares Out | 53.22M | 47.37M | 44.23M | 39.92M | 39.88M | 39.56M | 37.65M | 34.35M | 30.33M | 24.67M | 18.62M | 14.59M | 17.68M | 17.68M |
Weighted Avg Shares Out (Dil) | 53.22M | 47.37M | 48.46M | 39.92M | 39.88M | 39.56M | 37.65M | 34.35M | 30.33M | 24.67M | 18.62M | 14.59M | 17.68M | 17.68M |
Prothena shares buoyed by sale rumors
Prothena prepares for potential sale - Bloomberg News
Prothena: Switching From 'Hold' To 'Buy' On Lead Alzheimer's Drug Promise
Prothena (PRTA) Skyrockets 88.7% in 12 Months: Here's Why
Prothena to Participate in Upcoming Healthcare Conferences
Prothena (PRTA) Q2 Earnings and Revenues Miss Estimates
Prothena (PRTA) Reports Q2 Loss, Lags Revenue Estimates
Prothena Reports Second Quarter 2023 Financial Results and Business Highlights
Prothena: Dunn Appointment And Bristol Opt-In Boost Validation
Prothena Presents New Research in the Treatment of Alzheimer's Disease at Alzheimer's Association International Conference® 2023 (AAIC®)
Source: https://incomestatements.info
Category: Stock Reports